RT Conference Proceedings
T1 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC
A1 Arce-Lara, C.
A1 Arriola, E.
A1 Brunsvig, P.
A1 Carcereny, E.
A1 Domine, M.
A1 Dragnev, K.
A1 Felip, E.
A1 Garcia Campelo, R.
A1 Krebs, M.
A1 Paz-Ares, L.
A1 Ponce Aix, S.
A1 Spicer, J.
A1 Trigo, J. M.
A1 Vinolas Segarra, N.
A1 Holt, R.
A1 Micklem, D.
A1 Brown, A.
A1 Chisamore, M.
A1 Lorens, J.
K1 Axl
K1 pembrolizumab
K1 combination
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-10-01
LK https://hdl.handle.net/10668/26868
UL https://hdl.handle.net/10668/26868
LA en
DS RISalud
RD Apr 8, 2025